Consistent with our findings, we observed that RIC8A loss-of-function mutations were four times more likely to occur in HR-deficient ER+ BC (7.4%) than in wild-type controls (2.0%) in this cohort (see the “Methods” section, Fig. 4h, P = 0.04, Fisher’s exact test). Here, RIC8A is linked to breast cancer.